Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
EUCRW was delisted on the 26th of April, 2023.
25 hedge funds and large institutions have $1.08M invested in Eucrates Biomedical Acquisition Corp. Warrant in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 24 → 25 (+1)
1% more capital invested
Capital invested by funds: $1.07M → $1.08M (+$11.6K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIM
Cowen Investment Management
New York
|
+$1.19K |
| 2 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$939 |
| 3 |
SIA
Schechter Investment Advisors
Birmingham,
Michigan
|
+$929 |
| 4 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$898 |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$571 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6K |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$5K |
| 3 |
Goldman Sachs
New York
|
-$4.79K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.22K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1K |
EUCRW Hedge Fund Activity: Q4 2022 in Review
25 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) for Q4 2022, worth a combined $1.08M — up 1.1% from $1.07M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EUCRW positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Cowen Investment Management, opening a new position worth an estimated $1.19K. The largest seller was BlackRock, exiting entirely with an estimated $6K sold.
- 25 institutional investors held Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) as of Q4 2022, up from 24 in Q3 2022.
- Funds reported $1.08M of Eucrates Biomedical Acquisition Corp. Warrant stock for Q4 2022, up 1.1% quarter-over-quarter.
- 5 funds opened new Eucrates Biomedical Acquisition Corp. Warrant positions in Q4 2022 and 4 closed out, a net change of +1 holder.
- The largest Eucrates Biomedical Acquisition Corp. Warrant buyer in Q4 2022 was Cowen Investment Management, an estimated $1.19K added.
- The largest Eucrates Biomedical Acquisition Corp. Warrant seller in Q4 2022 was BlackRock, an estimated $6K sold.
Based on aggregated 13F filings for Q4 2022.